Patents by Inventor Hong-Chul Yoon
Hong-Chul Yoon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11932618Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.Type: GrantFiled: March 13, 2023Date of Patent: March 19, 2024Assignee: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Hong Chul Yoon, Kyung Mi An, Myong Jae Lee, Jin Hee Lee, Jeong-geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-Eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
-
Publication number: 20230373954Abstract: The present invention provides a novel compound represented by Chemical Formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.Type: ApplicationFiled: August 1, 2023Publication date: November 23, 2023Inventors: Hong Chul Yoon, Joon Tae Park, Jung Woo Lee, Kyung Mi An, A Rang IM, Woo Jin Jeon, Jae Ho Heo, Chang Hee Hong, Jung Eun Park, Te Ik Sohn, Da Hae Hong, Jung Ho Kim, Jae Eui Shin, Yeong Ran Yoo, Min Whan Chang, In Gyu Je, Su Yeon Kang, Yoon Sung Song, Joo Yun Lee
-
Patent number: 11767311Abstract: The present invention provides a novel compound represented by Chemical Formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.Type: GrantFiled: June 16, 2021Date of Patent: September 26, 2023Assignee: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Hong Chul Yoon, Joon Tae Park, Jung Woo Lee, Kyung Mi An, Rang A Im, Woo Jin Jeon, Jae Ho Heo, Chang Hee Hong, Jung Eun Park, Te Ik Sohn, Da Hae Hong, Jung Ho Kim, Jae Eui Shin, Yeong Ran Yoo, Min Whan Chang, In Gyu Je, Su Yeon Kang, Yoon Sung Song, Joo Yun Lee
-
Publication number: 20230212140Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.Type: ApplicationFiled: March 13, 2023Publication date: July 6, 2023Inventors: Hong Chul Yoon, Kyung Mi, myong Jae Lee, Jin Hee Lee, Jeong-Geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-Eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
-
Publication number: 20230192650Abstract: The present invention provides a novel compound represented by Chemical Formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.Type: ApplicationFiled: June 16, 2021Publication date: June 22, 2023Inventors: Hong Chul Yoon, Joon Tae Park, Jung Woo Lee, Kyung Mi An, Rang A IM, Woo Jin Jeon, Jae Ho Heo, Chang Hee Hong, Jung Eun Park, Te Ik Sohn, Da Hae Hong, Jung Ho Kim, Jae Eui Shin, Yeong Ran Yoo, Min Whan Chang, In Gyu Je, Su Yeon Kang, Yoon Sung Song, Joo Yun Lee
-
Patent number: 11643403Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.Type: GrantFiled: November 13, 2020Date of Patent: May 9, 2023Assignee: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Hong Chul Yoon, Kyung Mi An, Myong Jae Lee, Jin Hee Lee, Jeong-geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-Gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
-
Publication number: 20230013143Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.Type: ApplicationFiled: November 13, 2020Publication date: January 19, 2023Inventors: Hong Chul Yoon, Kyung Mi An, Myong Jae Lee, Jin Hee Lee, Jeong-geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
-
Publication number: 20230002348Abstract: The present invention provides novel compounds of chemical formula 1, optical isomers of the compounds, or a pharmaceutically acceptable salts of the compounds, or the optical isomers. The compounds, isomers, and salts exhibits excellent activity as GLP-1 receptor agonists. Particularly, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used therapeutic agents for metabolic diseases. In addition, they exhibits excellent pharmacological safety for cardiovascular systems.Type: ApplicationFiled: November 13, 2020Publication date: January 5, 2023Inventors: Hong Chul Yoon, Kyung Mi An, Myong Jae Lee, Jin Hee Lee, Jeong-geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-Eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-Gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
-
Patent number: 9199965Abstract: Disclosed herein are novel benzoimidazole derivatives functioning as antagonists to vanilloid receptor-1, and a pharmaceutical composition comprising the same. They are useful in preventing or treating pain, acute pain, chronic pain, neuropathic pain, postoperative pain, migraines, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neurological illness, neurodermatitis, strokes, bladder hypersensitivity, irritable bowel syndrome, respiratory disorders such as asthma, chronic obstructive pulmonary disease, etc., burns, psoriasis, itching, vomiting, irritation of the skin, eyes, and mucous membranes, gastric-duodenal ulcers, inflammatory intestinal diseases, and inflammatory diseases.Type: GrantFiled: January 27, 2006Date of Patent: December 1, 2015Assignee: Daewoong Co., Ltd.Inventors: Ji Duck Kim, Hong Chul Yoon, In Woo Kim, Hyae Jung Hyun
-
Patent number: 9040572Abstract: This invention relates to a method of preparing a benzoimidazole derivative at high purity and high yield so as to enable the production of the benzoimidazole derivative compound as an antagonist against a vanilloid reactor-1, and particularly to a method of preparing a benzoimidazole derivative at high purity and high yield, wherein the benzoimidazole derivative is synthesized using a novel intermediate, namely, benzaldehyde, and thereby the preparation process is simple so that it can be applied to production.Type: GrantFiled: September 27, 2011Date of Patent: May 26, 2015Assignee: Daewoong Pharmaceutical Co., Ltd.Inventors: In Woo Kim, Ji Duck Kim, Hong Chul Yoon, Hee Kyoon Yoon, Byung Goo Lee, Joon Hwan Lee, Young Mook Lim, Soo Jin Choi
-
Patent number: 8940769Abstract: Disclosed are biaryl benzoimidazole derivatives. They have an inhibitory effect on calcium influx in HEK cells, thereby showing a powerful antagonistic effect on a vanilloid receptor, and further have an analgesic effect, thereby being useful for preventing or treating pain, acute pain, chronic pain, neuropathic pain, postoperative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurological illness, neurodermatitis, stroke, bladder hypersensitivity, irritable bowel syndrome, a respiratory disorder such as cough, asthma, and chronic obstructive pulmonary disease, burning, psoriasis, itching, vomiting, irritation of the skin, eyes, and mucous membranes, gastric-duodenal ulcers, inflammatory intestinal diseases, and inflammatory diseases.Type: GrantFiled: April 5, 2013Date of Patent: January 27, 2015Assignee: Daewoong Pharmaceutical Co., Ltd.Inventors: Ji Duck Kim, Hong-Chul Yoon, In Woo Kim, Hyae Jung Hyun
-
Publication number: 20130231477Abstract: This invention relates to a method of preparing a benzoimidazole derivative at high purity and high yield so as to enable the production of the benzoimidazole derivative compound as an antagonist against a vanilloid reactor-1, and particularly to a method of preparing a benzoimidazole derivative at high purity and high yield, wherein the benzoimidazole derivative is synthesized using a novel intermediate, namely, benzaldehyde, and thereby the preparation process is simple so that it can be applied to production.Type: ApplicationFiled: September 27, 2011Publication date: September 5, 2013Applicant: DAEWOONG PHARMACEUTICAL CO., LTD.Inventors: In Woo Kim, Ji Duck Kim, Hong Chul Yoon, Hee Kyoon Yoon, Byung Goo Lee, Joon Hwan Lee, Young Mook Lim, Soo Jin Choi
-
Patent number: 8436022Abstract: Disclosed are biaryl benzoimidazo derivatives. They have an inhibitory effect on calcium influx in HEK cells, thereby showing a powerful antagonistic effect on a vanilloid receptor, and further have an analgesic effect, thereby being useful for preventing or treating pain, acute pain, chronic pain, neuropathic pain, postoperative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurological illness, neurodermatitis, stroke, bladder hypersensitivity, irritable bowel syndrome, a respiratory disorder such as cough, asthma, and chronic obstructive pulmonary disease, burning, psoriasis, itching, vomiting, irritation of the skin, eyes, and mucous membranes, gastric-duodenal ulcers, inflammatory intestinal diseases, and inflammatory diseases.Type: GrantFiled: July 11, 2007Date of Patent: May 7, 2013Assignee: Daewoong Pharmaceutical Co., Ltd.Inventors: Ji Duck Kim, Hong-Chul Yoon, In Woo Kim, Hyae Jung Hyun
-
Patent number: 8362012Abstract: The present invention relates to a novel benzoxazine benzimidazole derivative of formula (1) as an antagonist against a vanilloid receptor-1, a pharmaceutical composition comprising the same as an active ingredient, and a use thereof. The benzoxazine benzimidazole derivative of the present invention may be useful for preventing or treating a disease associated with antagonistic activity of vanilloid receptor-1: wherein, R1, R2, R3, R3?, Q1, Q2, Q3 and Q4 have same meanings as defined in the specification.Type: GrantFiled: April 16, 2009Date of Patent: January 29, 2013Assignee: Daewoong Pharmaceutical Co., Ltd.Inventors: Ji Duck Kim, Hong-Chul Yoon, Seong Hee Cho, Inwoo Kim, Min Jae Cho, In Young Lee, Hyae Jung Hyun, Eunkyung Park
-
Patent number: 8026235Abstract: Discloses is a benzoxazine benzimidazole derivative, represented by Chemical Formula 1, functioning as an antagonist to the vanilloid receptor-1, a pharmaceutical composition comprising the same, and the use thereof. The benzoxazine benzimidazole derivative can be useful for preventing or treating a disease associated with antagonistic activity of vanilloid receptor-1, without hyperthermia: wherein, R1, R2, R3, R4 and R5 are as defined in the specification.Type: GrantFiled: October 21, 2010Date of Patent: September 27, 2011Assignee: Daewoong Pharmaceutical Co., Ltd.Inventors: Ji Duck Kim, Hong-Chul Yoon, In Woo Kim, Min Jae Cho, In Young Lee, Sang Ho Lee, Eun Kyung Park, Kwon Jo Lim, Sang Hyun Nam
-
Publication number: 20110086849Abstract: The present invention relates to a novel benzoxazine benzimidazole derivative of formula (1) as an antagonist against a vanilloid receptor-1, a pharmaceutical composition comprising the same as an active ingredient, and a use thereof. The benzoxazine benzimidazole derivative of the present invention may be useful for preventing or treating a disease associated with antagonistic activity of vanilloid receptor-1: wherein, R1, R2, R3, R3?, Q1, Q2, Q3 and Q4 have same meanings as defined in the specification.Type: ApplicationFiled: April 16, 2009Publication date: April 14, 2011Applicant: DAEWOONG PHARMACEUTICALS CO., LTD.Inventors: Ji Duck Kim, Hong-Chul Yoon, Seong Hee Cho, Inwoo Kim, Min Jae Cho, IN Young Lee, Hyae Jung Hyun, Eunkyung Park
-
Publication number: 20090209540Abstract: Disclosed are biaryl benzoimidazole derivatives. They have an inhibitory effect on calcium influx in HEK cells, thereby showing a powerful antagonistic effect on a vanilloid receptor, and further have an analgesic effect, thereby being useful for preventing or treating pain, acute pain, chronic pain, neuropathic pain, postoperative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurological illness, neurodermatitis, stroke, bladder hypersensitivity, irritable bowel syndrome, a respiratory disorder such as cough, asthma, and chronic obstructive pulmonary disease, burning, psoriasis, itching, vomiting, irritation of the skin, eyes, and mucous membranes, gastric-duodenal ulcers, inflammatory intestinal diseases, and inflammatory diseases.Type: ApplicationFiled: July 11, 2007Publication date: August 20, 2009Applicant: DAEWOONG PHARMACEUTICAL CO., LTD.Inventors: Ji Duck Kim, Hong-Chul Yoon, In Woo Kim, Hyae Jung Hyun
-
Publication number: 20090018124Abstract: Disclosed herein are novel benzoimidazole derivatives functioning as antagonists to vanilloid receptor-1, and a pharmaceutical composition comprising the same. They are useful in preventing or treating pain, acute pain, chronic pain, neuropathic pain, postoperative pain, migraines, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neurological illness, neurodermatitis, strokes, bladder hypersensitivity, irritable bowel syndrome, respiratory disorders such as asthma, chronic obstructive pulmonary disease, etc., burns, psoriasis, itching, vomiting, irritation of the skin, eyes, and mucous membranes, gastric-duodenal ulcers, inflammatory intestinal diseases, and inflammatory diseases.Type: ApplicationFiled: January 26, 2006Publication date: January 15, 2009Inventors: Ji Duck Kim, Hong Chul Yoon, In Woo Kim, Hyae Jung Hyun